journal
Journals Therapeutic Advances in Medica...

Therapeutic Advances in Medical Oncology

https://read.qxmd.com/read/38680292/pembrolizumab-induced-nephrotoxicity-in-a-patient-with-breast-cancer
#21
Samer Alkassis, Kasey Fitzsimmons, Sara Hurvitz
The introduction of immunotherapy has revolutionized the treatment and improved outcomes of multiple types of cancer. Although breast cancer is a less immune-responsive tumor type, the incorporation of pembrolizumab into chemotherapy regimens in the neoadjuvant and first-line metastatic setting for the triple-negative disease has improved outcomes. However, the use of this type of treatment is associated with a spectrum of adverse events. Although rarely affected, kidneys can be a target for immunotherapy, leading to irreversible injury if not recognized and addressed early...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38680291/dysregulation-of-base-excision-repair-factors-associated-with-low-tumor-immunogenicity-in-head-and-neck-cancer-implication-for-immunotherapy
#22
JOURNAL ARTICLE
Zackary Shpilman, Dawit Kidane
BACKGROUND: Head and neck squamous carcinoma (HNSCC) is caused by different exogenous risk factors including smoking cigarettes, alcohol consumption, and HPV infection. Base excision repair (BER) is the frontline to repair oxidative DNA damage, which is initiated by the DNA N -glycosylase proteins (OGG1) and other BER factors including DNA polymerase β (POLB). OBJECTIVE: Explore whether BER genes' ( OGG1 , POLB ) overexpression in HNSCC alters genomic integrity, immunogenicity, and its role in prognostic value...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38680290/treatment-with-nanosomal-paclitaxel-lipid-suspension-versus-conventional-paclitaxel-in-metastatic-breast-cancer-patients-a-multicenter-randomized-comparative-phase-ii-iii-clinical-study
#23
JOURNAL ARTICLE
Chiradoni Thungappa Satheesh, Rakesh Taran, Jitendra Kumar Singh, Shanti Prakash Shrivastav, Nikunj K Vithalani, Kalyan Kusum Mukherjee, Rajnish Vasant Nagarkar, Tanveer Maksud, Ajay Omprakash Mehta, Krishnan Srinivasan, Mummaneni Vikranth, Satish Ramkrishna Sonawane, Ateeq Ahmad, Saifuddin Sheikh, Shoukath M Ali, Ronak Patel, Mahesh Paithankar, Lav Patel, Anil Rajani, Deepak Bunger, Alok Chaturvedi, Imran Ahmad
BACKGROUND: A novel nanosomal paclitaxel lipid suspension (NPLS), free from Cremophor EL (CrEL) and ethanol, was developed to address the solvent-related toxicities associated with conventional paclitaxel formulation. OBJECTIVE: To evaluate the efficacy and safety of NPLS versus CrEL-based paclitaxel (conventional paclitaxel) in patients with metastatic breast cancer (MBC). DESIGN: A prospective, open-label, randomized, multiple-dose, parallel, phase II/III study...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38665845/improving-olaparib-exposure-to-optimize-adverse-effects-management
#24
JOURNAL ARTICLE
Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt
BACKGROUND: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. OBJECTIVES: This work aimed to describe the pharmacokinetics/pharmacodynamics (PK/PD) relationship between olaparib plasma concentrations and common adverse effects (i.e. anaemia and hypercreatininaemia), in a real-life setting, to propose a target concentration for therapeutic drug monitoring...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38655393/assessing-the-effectiveness-of-targeted-agents-in-adjuvant-therapy-for-patients-with-metastatic-colorectal-cancer-undergoing-surgical-resection-a-retrospective-cohort-study
#25
JOURNAL ARTICLE
Yi-Chia Su, Chih-Chien Wu, Yu-Hsun Chen, Chien-Chou Su, Yu-Ching Chang, Meng-Che Hsieh, Yea-Huei Kao Yang
BACKGROUND: Primary tumor resection and metastasectomy may be beneficial for many patients with metastatic colorectal cancer (mCRC). OBJECTIVE: To assess the differences in postoperative survival outcomes between adjuvant therapy with chemotherapy alone and chemotherapy plus targeted agents (TAs). DESIGN: Retrospective cohort study. METHODS: Patients with mCRC who underwent surgical resection for primary colorectal tumor and distant metastases and received adjuvant therapy from 1 January 2010 to 31 December 2017 were enrolled in the Taiwan Cancer Registry...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38645422/navigating-uncharted-territory-a-case-report-and-literature-review-on-the-remarkable-response-to-personalized-crizotinib-containing-combinational-therapy-in-a-pazopanib-refractory-patient-with-novel-alterations
#26
Esranur Aydın, Ünal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
This paper presents a patient with a novel Ig-like-III domain fibroblast growth factor receptor (FGFR2) alteration (W290_P307>C) along with CDKN2A/B alterations and a cadherin 1 (CDH1) alteration. Initial responsiveness to pazopanib monotherapy was encouraging, yet progression occurred after 7.5 months. Following progression, the molecular tumor board recommended a combination therapy approach comprising pazopanib, crizotinib, and palbociclib to target all of the changed pathways at the same time...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38638285/personalized-treatment-with-parp-inhibitors-in-advanced-urothelial-carcinoma-a-case-report-and-literature-review
#27
Noura Abbas, Laudy Chehade, Ali Shamseddine
Bladder cancer (BC) poses a significant health challenge, particularly in metastatic cases, where the prognosis is unfavorable and therapeutic options are limited. Poly ADP-ribose polymerase (PARP) inhibitors have gained approval for use in various cancer types, but their application in BC remains controversial, despite the notable prevalence of DNA damage response alterations in advanced or metastatic urothelial carcinomas. In this report, we describe a 66-year-old heavy-smoking female diagnosed with muscle-invasive BC...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38628554/real-world-experience-supporting-the-role-of-oncologic-resection-and-adjuvant-chemotherapy-in-biliary-tract-cancers
#28
JOURNAL ARTICLE
Melina Boutin, Tharani Krishnan, Maria Safro, Jenny Yang, Helia Jafari, Janine M Davies, Sharlene Gill
BACKGROUND: Complete resection followed by adjuvant chemotherapy is the gold standard for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC). However, this is not always feasible, and recurrence rates remain high. OBJECTIVES: To understand the real-world proportions and reason for treatment failure in resected biliary tract cancers. DESIGN AND METHODS: We performed a retrospective population-based review of patients with GBC or CC [intrahepatic (IHCC) or extrahepatic (EHCC)] resected between 2005 and 2019 using the BC Cancer provincial database...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38617024/real-world-study-of-hepatic-artery-infusion-chemotherapy-combined-with-anti-pd-1-immunotherapy-for-hepatocellular-carcinoma-patients-with-portal-vein-tumor-thrombus
#29
JOURNAL ARTICLE
Jinghuan Li, Bing Quan, Wenfeng Liu, Menglong Zhao, Fan Yao, Rongxin Chen, Zhenggang Ren, Xin Yin
BACKGROUND: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) present a poor prognosis. Current systemic therapies offer limited benefits. Hepatic artery infusion chemotherapy (HAIC) is a local regional treatment for advanced HCC, particularly in selected patients such as patients with PVTT or high intrahepatic tumor burden. OBJECTIVES: The purpose of this study is to retrospectively evaluate the efficacy and safety of HAIC combined with anti-PD-1 immunotherapy for HCC patients with PVTT, and explore factors related to survival prognosis, providing clues for treatment decisions for HCC patients...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38617023/clinicopathologic-characteristics-of-hpv-associated-head-and-neck-squamous-cell-carcinoma-in-southern-china-long-term-retrospective-study-of-400-cases
#30
JOURNAL ARTICLE
Mingyuan Du, Qiaohong Lin, Shida Yan, Xianlu Gao, Chulin Yang, Zhaoyang Li, Wei Liao, Ankui Yang, Shuwei Chen
BACKGROUND: Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is an evolving and growing disease, especially in developing countries. However, the clinical characteristics of HPV-associated HNSCC in regard to HPV infection rates, patient features, and prognosis are under-reported in the Asian population. METHODS: In this study, we retrospectively enrolled a 400-case cohort of HNSCC with p16 immunochemistry and analyzed with long-term follow-up...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38606165/unraveling-the-tumor-immune-microenvironment-of-lung-adenocarcinoma-using-single-cell-rna-sequencing
#31
REVIEW
Lele Song, Yuan Gong, Erpeng Wang, Jianchun Huang, Yuemin Li
Tumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly influence lung cancer development and therapeutic outcome. The heterogeneity of TIME is composed of dynamic immune-related components, including various cancer cells, immune cells, cytokine/chemokine environments, cytotoxic activity, or immunosuppressive factors...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38606164/reactive-cutaneous-capillary-endothelial-proliferation-following-camrelizumab-monotherapy-or-combination-therapy-for-multi-cancers-a-large-scale-pooled-analysis-of-10-studies-in-china
#32
JOURNAL ARTICLE
Wenshu Qu, Feng Wang, Shukui Qin, Yuqi Sun, Chuanpei Huang
BACKGROUND: Skin toxicities are the most common adverse events related to immunotherapy, such as reactive cutaneous capillary endothelial proliferation (RCCEP) following treatment with the anti-programmed cell death-1 antibody camrelizumab. OBJECTIVE: This study aimed to comprehensively analyze the clinical features and prognostic value of RCCEP in patients with malignancies who received camrelizumab alone (Camre) or in combination with the angiogenesis-targeted agent apatinib (Camre-Apa) or chemotherapy (Camre-Chemo)...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38606163/hr-positive-her2-negative-breast-cancer-arising-in-patients-with-or-without-brca2-mutation-different-biological-phenotype-and-similar-prognosis
#33
JOURNAL ARTICLE
Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan, Qiao-Yan Zhu, Yu-Yang Liao, Xiao-Wen Ding, Lin-Feng Zheng, Wen-Ming Cao
BACKGROUND: BRCA2 plays a key role in homologous recombination. However, information regarding its mutations in Chinese patients with breast cancer remains limited. OBJECTIVES: This study aimed to assess the clinicopathological characteristics of BRCA2 mutation breast cancer and explore the mutation's effect on hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer survival in China. DESIGN: This hospital-based cohort study prospectively included 629 women with breast cancer diagnosed from 2008 to 2023 at Zhejiang Cancer Hospital in China...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38584763/integration-of-liposomal-irinotecan-in-the-first-line-treatment-of-metastatic-pancreatic-cancer-try-to-do-not-think-about-the-white-bear
#34
REVIEW
Davide Melisi, Simona Casalino, Silvia Pietrobono, Alberto Quinzii, Camilla Zecchetto, Valeria Merz
The approval of novel therapeutic agents remains widely reliant on evidence derived from large phase III randomized controlled trials. Liposomal irinotecan (ONIVYDE® ) stands out as the only drug that has demonstrated improved survival both as a first-line therapy in combination with oxaliplatin and 5-fluorouracil/leucovorin (5FU/LV) (NALIRIFOX) compared to the standard gemcitabine plus nab-paclitaxel in the NAPOLI3 trial, and as a second-line treatment in combination with 5FU/LV compared to the standard 5FU/LV in the NAPOLI1 trial...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38559613/time-interval-between-surgery-and-adjuvant-chemotherapy-in-patients-with-gastric-cancer-after-gastrectomy-a-population-based-cohort-study-using-a-nationwide-claim-database
#35
JOURNAL ARTICLE
Chi Hoon Maeng, Hoseob Kim, Mina Kim
BACKGROUND: Adjuvant chemotherapy can reduce recurrence rates by eradicating microscopic metastases which may persist after curative resection. However, the optimal time interval (TI) between the surgery and chemotherapy remains controversial. OBJECTIVES: This study investigated the optimal TI between surgery and chemotherapy. DESIGN: A population-based cohort study using a nationwide claims database. METHODS: The data were obtained from the Korean National Health Insurance Service (NHIS) of Korea...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38559612/perioperative-and-palliative-systemic-treatments-for-biliary-tract-cancer
#36
REVIEW
Hossein Taghizadeh, Yawen Dong, Thomas Gruenberger, Gerald W Prager
Due to the fact biliary tract cancer (BTC) is often diagnosed at an advanced stage, thus, not eligible for resection, and due to the aggressive tumor biology, it is considered as one of the cancer types with the worst prognosis. Advances in diagnosis, surgical techniques, and molecular characterization have led to an improvement of the prognosis of BTC patients, recently. Although neoadjuvant therapy is expected to improve surgical outcomes by reducing tumor size, its routine is not well established. The application of neoadjuvant therapy in locally advanced disease may be indicated, the routine use of systemic therapy prior to surgery for cholangiocarcinoma patients with an upfront resectable disease is less well established, but discussed and performed in selected cases...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38559611/exceptional-synergistic-response-of-parp-inhibitor-and-immune-checkpoint-inhibitor-in-esophageal-adenocarcinoma-with-a-germline-brca2-mutation-a-case-report
#37
Himil Mahadevia, Ben Ponvilawan, Ammar Al-Obaidi, Jennifer Buckley, Janakiraman Subramanian, Dhruv Bansal
Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in various tumors. A significant therapeutic challenge with either ICIs or PARP inhibitors as monotherapy is treatment failure from intrinsic primary resistance or the development of secondarily acquired resistance after a period of responsiveness. The combination of PARP inhibitors and ICIs could mitigate this by potentiating treatment response. We describe an 83-year-old male patient who initially presented with abdominal pain, and weight loss along with alternating constipation and diarrhea...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38529270/from-biology-to-clinical-practice-antiproliferative-effects-of-somatostatin-analogs-in-neuroendocrine-neoplasms
#38
REVIEW
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
Somatostatin analogs (SSA), specifically octreotide and lanreotide, have demonstrated antiproliferative effects in patients with neuroendocrine tumors (NET), a group of rare malignancies of diverse origin and presentation. A prominent feature of NET cells is the expression of G protein-coupled receptors called somatostatin receptors (SSTR). Although these SSTR are not uniformly present in NET, they can be instrumental in the diagnosis and treatment of NET. Apart from their application in nuclear imaging and radionuclide therapy, SSA have proven invaluable in the treatment of hormonal syndromes associated with certain NET (antisecretory effects of SSA), but it took more than two decades to convincingly demonstrate the antiproliferative effects of SSA in metastatic NET with the two pivotal studies PROMID and CLARINET...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38523846/analysis-of-tumor-mutational-burden-and-mutational-landscape-comparing-whole-exome-sequencing-and-comprehensive-genomic-profiling-in-patients-with-resectable-early-stage-non-small-cell-lung-cancer
#39
JOURNAL ARTICLE
Su-Jin Choi, Jii Bum Lee, Jae Hwan Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
BACKGROUND: Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small-cell lung cancer (NSCLC). However, the role of CGP remains elusive in resectable NSCLC. Here, we elucidate the feasibility of CGP in early-stage NSCLC Korean patients and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms. METHODS: All surgically resected NSCLC samples ( N  = 96) were analyzed to assess the concordance in TMB calculation and targetable mutations using whole-exome sequencing (WES) and TruSight Oncology 500 (TSO500)...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38510678/bone-metastasis-in-non-small-cell-lung-cancer-genomic-characterization-and-exploration-of-potential-targets
#40
JOURNAL ARTICLE
Jiali Gong, Shumin Hu, Qianyun Shan, Jing Qin, Na Han, Fajun Xie, Hongyang Lu
BACKGROUND: Bone metastasis (BM) seriously affects the quality of life and reduces the survival time of patients with non-small-cell lung cancer (NSCLC). The genomic characteristics and potential targets of BMs are yet to be fully explored. OBJECTIVE: To explore the genetic characteristics and potential targets of BM in NSCLC. DESIGN: In all, 83 patients with NSCLC were retrospectively selected in this study. Genomic characterization of BMs was explored with the analysis of NGS results from primary tumors and BMs in 6 patients, then combined with NGS results of lung tumors in 16 patients with initial recurrence in bone to analyze mutations potentially associated with BMs, and finally, the correlation was further validated in 61 postoperative patients...
2024: Therapeutic Advances in Medical Oncology
journal
journal
42443
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.